CONFIDENTIAL once completed.

2023 Annual Survey of Research and Development of Canadian Private Non-Profit Organizations Selon nos dossiers votre langue de préférence est l'anglais, si vous préférez recevoir ce document en français, veuillez nous appeler au numéro sans frais suivant : 1-800-972-9692



This information is collected under the authority of the *Statistics Act*, Revised Statutes of Canada, 1985, Chapter S-19. COMPLETION OF THIS QUESTIONNAIRE IS A LEGAL REQUIREMENT UNDER THIS ACT.

Introduction

Survey purpose

The survey collects information on scientific activities of Canadian private non-profit organizations. The research and development expenditures and personnel information is used by federal, provincial and territorial governments and agencies, academics and international organizations for statistical analyses and policy purposes. These data also contribute to national totals of research and development activities. The payments and receipts information is used by these agencies to monitor knowledge flows across international borders and between Canadian organizations.

Your information may also be used by Statistics Canada for other statistical and research purposes.

Security of emails and faxes

Statistics Canada advises you that there could be a risk of disclosure during facsimile or email. However upon receipt, Statistics Canada will provide the guaranteed level of protection afforded all information collected under the authority of the *Statistics Act*.

Note: Our online questionnaires are secure, there is no risk of data interception when responding to Statistics Canada online surveys.

Confidentiality

The *Statistics Act* protects the confidentiality of information collected by Statistics Canada.

Data-sharing agreements

To reduce response burden, Statistics Canada has entered into data-sharing agreements with provincial and territorial statistical agencies and other government organizations, which have agreed to keep the data confidential and use them only for statistical purposes.

Information on confidentiality, data sharing agreements and record linkages can be found on the last page of this questionnaire.

Please return the questionnaire within 30 days.

Please mail the completed questionnaire in the enclosed envelope or fax it to Statistics Canada at 1-888-883-7999.

If you are unable to complete within 30 days **or** if you need help, call us at **1-877-604-7828** or **TTY 1-800-363-7629**.

Statistics Canada Operations and Integration Division 150 Tunney's Pasture Driveway Ottawa, Ontario K1A 0T6

Visit our website, www.statcan.gc.ca

5-3600-4204.1: 2024-01-29



Canadä

| В | usiness or organization and contact | information | | | | | |
|----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------|--|--|--|--|--|
| 1. | Verify or provide the business or organization's legal and operating name, and correct information if needed. Note: Legal name modifications should only be done to correct a spelling error or typo. | | | | | | |
| | Legal name | Operating name (if applicable) | | | | | |
| | | | | | | | |
| 2. | information if needed. | designated contact person for the business or organization, and correct eceive this questionnaire. The designated contact person may not always be the one who | | | | | |
| | First name | Last name | | | | | |
| | | | | | | | |
| | Title | Preferred language of communication | | | | | |
| | | English French | | | | | |
| | Mailing address (number and street) | | | | | | |
| | City | Province, territory or state | | | | | |
| | | | | | | | |
| | Postal code or ZIP code Example: A9A 9A9 or 12345-1234 | | | | | | |
| | Country | S | | | | | |
| | Email address Example: user@example.gov.ca | | | | | | |
| | | | | | | | |
| | Telephone number (including area code) Example: 123-123-1234 | Extension number (if applicable) | | | | | |
| | Fax number (including area code) Example: 123-123-1234 | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |

| Operational → Go to question 4 Not currently operational e.g., temporarily or permanently closed, change of ownership |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Not currently operational |
| |
| Why is this business or organization not currently operational? Why is this business or organization not currently operational? Seasonal operations Go to question 3a Ceased operations Go to question 3b |
| Sold operations \rightarrow Go to question 3c |
| Amalgamated with other businesses or organizations → Go to question 3d Temporarily inactive but expected to reopen → Go to question 3e |
| ⁷ No longer operating due to other reasons \rightarrow Go to question 3f |
| |
| 3a. Seasonal operations |
| When did this business or organization close for the season? |
| Date |
| When does this business or organization expect to resume operations? |
| Date → Go to question 4 |
| 3b. Ceased operations |
| When did this business or organization cease operations? |
| B00211 Date |
| Why did this business or organization cease operations? |
| |
| ² Liquidation |
| ³ Dissolution Go to question 4 |
| ⁴ Other |
| Specify the other reasons why operations ceased |
| L ₂ |

| 3c. Sold operations |
|---------------------------------------------------------------------------------|
| When was this business or organization sold? |
| B00212 Date |
| What is the legal name of the buyer? |
| → Go to question 4 |
| 3d. Amalgamated with other businesses or organizations |
| When did this business or organization amalgamate? |
| What is the legal name of the resulting or continuing business or organization? |
| |
| What are the legal names of the other amalgamated businesses or organizations? |
| → Go to question 4 |
| 3e. Temporarily inactive but expected to reopen |
| When did this business or organization become temporarily inactive? |
| When does this business or organization expect to resume operations? |
| Date |
| Why is this business or organization temporarily inactive? |
| → Go to question 4 |
| 3f. No longer operating due to other reasons |
| When did this business or organization cease operations? |
| Why did this business or organization cease operations? |
| |

| 1 | Verify or provide the current main activity of the business or organization identified by the legal and operating name. |
|----|-------------------------------------------------------------------------------------------------------------------------|
| | Note: The described activity was assigned using the North American Industry Classification System (NAICS). |
| | |
| | |
| E | 805002 |
| | This is the current main activity -> Go to next section |
| | ² This is not the current main activity |
| | Provide a brief but precise description of this business or organization's main activity |
| | e.g., breakfast cereal manufacturing, shoe store, software development |
| | |
| | |
| | |
| 5. | Was this business or organization's main activity ever classified as: |
| | |
| E | 805111 |
| | ¹ Yes |
| | ² No \rightarrow Go to next section |
| | |
| 6. | When did the main activity change? |
| | YYYY MM DD |
| | B00219 |
| | Date |
| | |
| | |
| | |
| | |
| | |
| | MFONO NON |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |

Reporting instructions

- Please print in ink.
- Report dollar amounts in thousands of Canadian dollars.
- Exclude sales tax.
- Percentages should be rounded to whole numbers.
- Report dollar amounts rounded to the nearest dollar.
- Where exact figures are not available, please provide the most accurate estimate possible.
- If this organization performs in-house research and development (R&D) and makes payments for R&D performed by other organizations, complete all questions.
- If this organization performs in-house research and development (R&D) and does not make payments for R&D performed by other organizations, complete questions 1 9, 11, 12 22.
- If this organization makes payments for R&D performed by other organizations and does not perform in-house R&D, complete questions 1 7, 9 11, 16, 20 22.
- If this organization does not perform in-house R&D and does not make payments for R&D performed by other organizations, complete questions 1 7, 9, 11, 16, 20 22.

WE ON A USE OF THE OF THE OP T

| CI | naracteristics |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Re | porting period |
| | YYYY MM DD |
| 1. | What is the end date of this organization's fiscal year? |
| | Note: For this survey, this organization's fiscal year end date should fall on or before March 31, 2024. |
| | Here are some examples of fiscal periods that fall within the targeted dates: |
| | May 1, 2022 to April 30, 2023 July 1, 2022 to June 30, 2023 October 1, 2022 to September 30, 2023 January 1, 2023 to December 31, 2023 February 1, 2023 to January 31, 2024 April 1, 2023 to March 31, 2024 |
| | *THIS FISCAL YEAR WILL BE REFERRED TO AS 2023 THROUGHOUT THE QUESTIONNAIRE |
| | |
| Or | ganization status |
| 2. | What is this organization's business number? (e.g., GST number or charitable registration number) |
| 3. | Is this organization affiliated with a hospital, a university or a government agency or department? |
| | B30006 1 Yes |
| | ² No |
| | CAN\$ '000 |
| 4. | In 2023, what were this organization's total expenditures within Canada? (If precise figures are not available, please provide your best estimate) |
| | CAN\$ '000 |
| 5. | In 2023, what were this organization's total wages and salaries within Canada? |
| | (If precise figures are not available, please provide your best estimate) \$,000 |
| | Number of employees |
| 6. | In 2023, what was the average number of employees in full-time equivalents (FTE) |
| | (If precise figures are not available, please provide your best estimate in full-time equivalents (FTE)) |
| | |
| FO | r this survey "In-house R&D" refers to: |
| | Expenditures within Canada for R&D performed within this organization by: |
| | employees (permanent, temporary or casual) self-employed individuals or contractors who are working on-site on this organization's R&D projects. |
| | "Payments for R&D performed by other organizations" refers to: |
| | Payments made within or outside Canada to other organizations, individuals or companies to fund R&D performance: • grants • fellowships |
| | • contracts. |

| In-house research and development (R&D) expenditures | | | | | | | | | |
|------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------|------------------|------------------|-------------------------------------|-----------------|--|--|--|
| 7. | 7. In 2023, 2024 and 2025, did this organization have or plan to make expenditures for R&D performed in-house within Canada? | | | | | | | | |
| | Exclude payments for R&D performed by others (e.g. , funding, grants or contracted out R&D expenditures), which should be reported in question 10. | | | | | | | | |
| | | ¹ Yes | | | | | | | |
| | | ² No b Go to question 9 | | | | | | | |
| 8. | | 2023, 2024 and 2025, what were this orgar hin Canada? | nization's a | ctual or planned | expenditures for R&D per | formed in-house | | | |
| | | ase report all amounts in thousands of Canadia port "0" for no R&D expenditures. | an dollars. | | | | | | |
| | | | Мас | le in 2023 | Planned in 2024 | Planned in 2025 | | | |
| | | rrent in-house R&D expenditures hin Canada | CA | AN\$ '000 | CAN\$ '000 | CAN\$ '000 | | | |
| | a. | Wages, salaries of permanent, | E45077_sr1 | | 1 2 | • | | | |
| | | temporary and casual R&D employees Include fringe benefits | \$ | ,000, | | | | | |
| | b. | Services to support R&D Include services of self-employed individuals | | \sim | | | | | |
| | | or contractors who are working on-site on this organization's R&D projects. | | | 2^{\vee} | | | | |
| | | Exclude contracted out or granted expenditures to other organizations to | E45077_sr2 | ,000 | | | | | |
| | | perform R&D (report in question 10) | Φ E45077_sr3 | ,000 | | | | | |
| | c. | R&D materials | \$ | ,000 | | | | | |
| | d. | All other current R&D costs | E45077_sr4 | ,000 | | | | | |
| | | Include overhead costs | | ,000 | | | | | |
| | | Total current in-house R&D | E45050 | | E45079 | E45082 | | | |
| | | expenditures within Canada | \$ | ,000 | \$,000 | \$,000 | | | |
| | | pital in-house R&D expenditures hin Canada | | | | | | | |
| | e. | Software | E45078_sr1 | | | | | | |
| | | Exclude capital depreciation | \$ E45078_sr2 | ,000 | | | | | |
| | f. | Land Exclude capital depreciation | \$ | ,000 | | | | | |
| | g. | Buildings and structures | E45078_sr3 | | | | | | |
| | | Exclude capital depreciation | \$ | ,000 | | | | | |
| | h. | Equipment, machinery and all other capital Exclude capital depreciation | E45078_sr4 | ,000, | | | | | |
| | | | | | | | | | |
| | | Total capital in-house R&D expenditures within Canada | E45060 | | \$.000 | £45083 | | | |
| | | | Ф Е45070 | ,000 | \$,000 | \$,000 | | | |
| | | Total in-house R&D expenditures within Canada | \$ | ,000 | | | | | |
| | | | | 1000 | | | | | |


IBSP — 2023 Annual Survey of Research and Development of Canadian Private Non-Profit Organizations

| _ | | | | | | | |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------|-------------------------------------------|--|--|--|
| Pa | yme | ents for R&D performed by other organizations | | | | | |
| 9. | In 2023, did this organization make payments to other organizations to perform R&D within Canada or outside Canada? Include: • funding or grants provided to other organizations to perform R&D • contracted out expenditures for R&D. | | | | | | |
| | | slude services of self-employed individuals or contractors who are working on-s in reported earlier as part of in-house R&D expenditures in question 8. | te on this organization's R | &D projects, which should have | | | |
| | B0515 | 2 tp 1 | | | | | |
| | | Yes | | | | | |
| | | No F Go to question 11 | | | | | |
| 10. | In 2 | 2023, what were this organization's R&D payments to other organizat | ions within Canada or c | outside Canada? | | | |
| | Plea | ase report all amounts in thousands of Canadian dollars. port "0" for no R&D expenditures." | | | | | |
| | | | Within Canada | Outside Canada | | | |
| | | | CAN\$ '000 | CAN\$ '000 | | | |
| | | | E46096_sr1 | E43039_sr1 | | | |
| | a. | Companies | ,000 | ,000 | | | |
| | | \sim | E46096_sr2 | E43039_sr2 | | | |
| | b. | Other private non-profit organizations | ,000 | 000, | | | |
| | | | E46096_sr3 | E43039_sr3 | | | |
| | c. | Industrial research institutes or associations | ,000 | 000, \$ | | | |
| | | O_{λ} | E46096_sr4 | E43039_sr4 | | | |
| | d. | Hospitals | ,000 | 000, \$ | | | |
| | | | E46096_sr5 | E43039_sr5 | | | |
| | e. | Universities | , | 000, \$ | | | |
| | | Federal government departments and agencies | E46096_sr6 | 2 | | | |
| | f. | Federal government departments and agencies | ,000 E46096_sr7 | J | | | |
| | g. | Provincial or territorial government departments, ministries and agencies | ,000 |) | | | |
| | | | E46096_sr8 | , | | | |
| | h. | Provincial or territorial research organizations | ,000 |) | | | |
| | i. | Other organizations | E46096_sr9 | E43039_sr6 | | | |
| | | e.g., individuals, non-university educational institutions, foreign governments | ,000 | 000. | | | |
| | | | E46210 | E43030 | | | |
| | | 2023 – Total payments for R&D performed by other organizations | | | | | |
| | | by other organizations | ,000 | \$,000 | | | |
| 11. | or c | 2024 and 2025, what are this organization's planned payments to othe putside Canada? | r organizations to perfo | rm R&D within Canada | | | |
| | кер | oort "0" for no R&D expenditures. | Within Canada | Outside Canada | | | |
| | | | CAN\$ '000 | CAN\$ '000 | | | |
| | | | E46097 | E43041 | | | |
| | | 2024 – Total payments for R&D performed by other organizations | | | | | |
| | | | E46098 |) \$,000 E43042 | | | |
| | | 2025 – Total payments for R&D performed by other organizations | | | | | |
| | | by other organizations | ,000 | ,000 | | | |

| Ge | Geographic distribution of in-house R&D expenditures within Canada in 2023 | | | | | | | |
|----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------|--------------------------------------|----------------------------------------------------------------------------------|--------------------------------------|--------------------------------------------------------------------------------|------|--|
| 12 | 12. In 2023, how were this organization's total expenditures for R&D performed in-house distributed by province or territory? Exclude: • payments for R&D performed by others (e.g., funding, grants or contracted out R&D expenditures), which should be reported in question 10 • capital depreciation. Please report all amounts in thousands of Canadian dollars. | | | | | | | |
| | | | Current in-house R&D expenditures | | Capital in-house R&D expenditures | | | |
| | | | | CAN\$ '000 | | CAN\$ '000 |) | |
| | | | | E45077_g1 | | E45078_g1 | | |
| | a. | Newfoundland and Labrador | \$ | ,00 |)0 \$ | | ,000 | |
| | | | | E45077_g2 | | E45078_g2 | | |
| | b. | Prince Edward Island | \$ | ,00 |)0 \$ | | ,000 | |
| | | | | E45077_g3 | | E45078_g3 | | |
| | с. | Nova Scotia | \$ | ,00 |)0 \$ | | ,000 | |
| | | | | E45077_g4 | | E45078_g4 | | |
| | d. | New Brunswick | \$ | ,00 |)0 \$ | | ,000 | |
| | | | | E45077_g5 | | E45078_g5 | | |
| | e. | Quebec | \$ | ,00 |)0 \$ | | ,000 | |
| | | | | E45077_g6 | | E45078_g6 | | |
| | f. | Ontario | \$ | ,00 |)0 \$ | | ,000 | |
| | | | | E45077_g7 | | E45078_g7 | | |
| | g. | Manitoba | \$ | ,00 |)0 \$ | 1 | ,000 | |
| | | | | E45077_g8 | | E45078_g8 | | |
| | h. | Saskatchewan | \$ | ,00 |)0 \$ | ,) | ,000 | |
| | | | | E45077_g9 | | E45078_g9 | | |
| | i. | Alberta | \$ | ,00 |)0 \$ |) | ,000 | |
| | | | | E45077_g10 | | E45078_g10 | | |
| | j. | British Columbia | \$ | ,00 |)0 \$ | | ,000 | |
| | | | | E45077_g11 | | E45078_g11 | | |
| | k. | Yukon | \$ | ,00 |)0 \$ | | ,000 | |
| | | · · · · · · · · · · · · · · · · · · · | | E45077_g12 | | E45078_g12 | | |
| | I. | Northwest Territories | \$ | ,00 |)0 \$ | | ,000 | |
| | | | | E45077_g13 | | E45078_g13 | | |
| | m. | Nunavut | \$ | ,00 |)0 \$ | 1) | ,000 | |
| | | | | E45100 | | E45110 | | |
| | | 2023 – Total current and capital in-house R&D expenditures | \$ | ,00 |)0 \$ | | ,000 | |
| | | | | Should equal total current in-house R&D expenditures from question 8 | | Should equal total capital in-house R&D expenditures from question |) | |

| Sourc | es of funds for in-house R&D expenditures in 2023 | | | | | |
|----------|-------------------------------------------------------------------------------------------------------------------------------------------------|----------|---------------------------------------------------------|-------------------|----------------------|----------|
| | 2023 , what were the sources of funds for this organization's total lude Canadian and foreign sources. | exp | penditures for R&D perf | orme | d in-house? | |
| Exc | clude: • payments for R&D performed by others (e.g., funding, grants or contracted out R&D expenditures), which should | | | | | |
| Ple | be reported in question 10 capital depreciation. ase report all amounts in thousands of Canadian dollars. | | From within Canada | | From outside Car | nada |
| | port "0" for no R&D expenditures. | | CAN\$ '000 | | CAN\$ '000 | |
| a. | Funds from this organization | | E64047 | | E63037 | |
| u. | Include interest payments, fundraising and other income | \$ | ,000 E65048 | \$ | E63038 | ,000 |
| h | Companies | \$ | .000 | \$ | | ,000, |
| b. c. | Companies Federal government grants or funding | ψ | | ψ | | ,000 |
| 0. | Include R&D grants or funding or R&D portion only of other grants or funding | \$ | E64048 | $\langle \rangle$ | | |
| d | Ecderal acyamment contracto | | E65049 | - 1 | | |
| d. | Federal government contracts Include R&D contracts or R&D portion only of other contracts | \$ | .000 | | | |
| | eographic distribution of provincial or territorial governme | ent | grants or funding ar | nd pi | rovincial or terr | ritorial |
| 90 | | go | Provincial or territorial vernment grants or funding | , | Provincial or territ | |
| | | | CAN\$ '000 | | CAN\$ '000 | |
| | | | E64049_g1 | | E65051_g1: | |
| e. | Newfoundland and Labrador | \$ | ,000 | \$ | | ,000, |
| | | | E64049_g2 | | E65051_g2 | |
| f. | Prince Edward Island | \$ | ,000 | \$ | | ,000, |
| | | | E64049_g3: | | E65051_g3 | |
| g. | Nova Scotia | \$ | ,000 | \$ | | ,000, |
| 9. | | | E64049_g4 | | E65051_g4 | |
| h | New Brunswick | \$ | ,000 | \$ | | ,000 |
| | | Ψ | E64049_g5 | Ψ | E65051_g5 | ,000 |
| i. | Quebec | \$ | ,000 | \$ | | ,000, |
| | QUEDEC | Ψ | E64049_g6 | Ψ | E65051_g6 | ,000 |
| i | Ontario | \$ | .000 | \$ | | ,000, |
| ١. | | Ψ | E64049_g7 | ψ | E65051_g7 | ,000 |
| k | Manitaba | \$ | .000 | \$ | | ,000, |
| k. | Manitoba | ψ | E64049_g8: | ψ | E65051_g8 | ,000 |
| | O selectede success | \$ | 000 | \$ | | 000 |
| Ι. | Saskatchewan | ψ | ,000 E64049_g9 | ψ | E65051_g9 | ,000 |
| | | ¢ | | ¢ | | 000 |
| m. | Alberta | \$ | ,000 E64049_g10 | \$ | E65051_g10 | ,000 |
| | | <i>•</i> | | <i>•</i> | | |
| n. | British Columbia | \$ | ,000 | \$ | | ,000 |
| | | | E64049_g11 | | E65051_g11 | |
| 0. | Yukon | \$ | ,000 | \$ | | ,000 |
| | | | E64049_g12 | | E65051_g12 | |
| p. | Northwest Territories | \$ | ,000 | \$ | | ,000 |
| | | | E64049_g13 | | E65051_g13 | |
| q. | Nunavut | \$ | ,000 | \$ | | ,000 |

IBSP — 2023 Annual Survey of Research and Development of Canadian Private Non-Profit Organizations



| dis | tributed by field(s) of research and development? | 14. In 2023, how were this organization's total expenditures for R&D performed in-house within Canada distributed by field(s) of research and development? | | | | | | | |
|------|------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------|------|--|--|--|--|--|--|
| Exe | clude: • payments for R&D performed by others (e.g., funding, grants or contracted out R&D expenditures), which should be reported in question 10 | | | | | | | | |
| | capital depreciation. ase report all amounts in thousands of Canadian dollars. | | | | | | | | |
| | port "0" for no R&D expenditures. | CAN\$ '0 | 00 | | | | | | |
| IVIE | edical and health sciences | E45084_y1 | | | | | | | |
| a. | Basic medicine | \$ E45084_y2 | ,000 | | | | | | |
| b. | Clinical medicine | \$ E45084_y3 | ,000 | | | | | | |
| c. | Health sciences | \$ | ,000 | | | | | | |
| | | E45084_y4 | | | | | | | |
| d. | Medical biotechnology | \$ E45084_y5 | ,000 | | | | | | |
| e. | Other medical sciences | \$ | ,000 | | | | | | |
| | \circ | E45120 | | | | | | | |
| | Total medical and health sciences | \$ | ,000 | | | | | | |
| Ot | her fields of research and development | E45085 | | | | | | | |
| f. | Natural and formal sciences | \$ | ,000 | | | | | | |
| | | E45086 | | | | | | | |
| g. | Engineering and technology | \$ E45087 | ,000 | | | | | | |
| h. | Software-related sciences and technologies | \$ | .000 | | | | | | |
| | | E45088 | , | | | | | | |
| i. | Agricultural sciences | \$ | ,000 | | | | | | |
| | | E45089 | 000 | | | | | | |
| j. | Social sciences and humanities . | \$ | ,000 | | | | | | |
| | 2023 - Total in-house R&D expenditures within Canada | E45130 | | | | | | | |
| | by field of research and development (should equal total in-house R&D expenditures from question 8) (sum of questions a. to j.) | \$ | ,000 | | | | | | |
| | | | | | | | | | |

| Na | atur | e of R&D for in-house R&D expenditures within Canada in 2023 | | | | | |
|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------|--------------|--|--|--|
| 15. | In : wit | 2023, how were this organization's total expenditures for R&D performed in-house hin Canada distributed by nature of R&D? | | | | | |
| | Basic research is experimental or theoretical work undertaken primarily to acquire new knowledge of the underlying foundation of phenomena and observable facts, without any particular application or use in view. | | | | | | |
| | | plied research is original investigation undertaken in order to acquire new knowledge. It is, how marily towards a specific, practical aim or objective. | ever, directed | | | | |
| | Experimental development is systematic work, drawing on knowledge gained from research and practical experience and producing additional knowledge, which is directed to producing new products or processes or to improving existing products or processes. | | | | | | |
| | (OE | CD. Frascati Manual: Proposed Standard for Surveys on Research and Experimental Development, 2015) | | | | | |
| | | | Percentag of total in-ho R&D expendit | use | | | |
| | | | E45091_y1 | 0/ | | | |
| | a. | Basic research | E45091_y2 | % | | | |
| | b. | Applied research | E45091_y3 | % | | | |
| | c. | Experimental development | | % | | | |
| | | | E45140 | | | | |
| | | Total percentage. | 1 0 | 0 % | | | |
| | | | | | | | |
| Re | sul | ts of R&D expenditures from 2021 to 2023 | | | | | |
| 16. | pe | ring the three (3) years 2021, 2022 and 2023 , did this organization's total expenditures for R&D rformed in-house and payments for R&D made within Canada or outside Canada lead to new nificant improvements to the following? | | | | | |
| | e.g | | 01 | | | | |
| | a. | | Yes | No | | | |
| | | Goods Include goods developed through new knowledge from research discoveries | | No | | | |
| | b. | Goods | Yes | No 2 2 | | | |
| | b. c. | Goods Include goods developed through new knowledge from research discoveries | Yes | 2 | | | |
| | | Goods Include goods developed through new knowledge from research discoveries | Yes | 2 | | | |
| | c. | Goods Include goods developed through new knowledge from research discoveries | Yes B10033 1 B10034 1 B10035 1 | 2 | | | |
| | c. d. | Goods Include goods developed through new knowledge from research discoveries | Yes B10033 1 B10034 1 B10035 1 B10036 1 | 2 | | | |
| | c. d. | Goods Include goods developed through new knowledge from research discoveries | Yes B10033 1 B10034 1 B10035 1 B10036 1 | 2 | | | |
| | c. d. | Goods Include goods developed through new knowledge from research discoveries | Yes B10033 1 B10034 1 B10035 1 B10036 1 | 2 | | | |
| | c. d. | Goods Include goods developed through new knowledge from research discoveries | Yes B10033 1 B10034 1 B10035 1 B10036 1 | 2 | | | |
| | c. d. | Goods Include goods developed through new knowledge from research discoveries | Yes B10033 1 B10034 1 B10035 1 B10036 1 | 2 | | | |

In-house R&D personnel in 2023

17. In 2023, how many in-house R&D personnel within Canada did this organization have in the following R&D occupations?

If this organization is unable to provide a gender breakdown of **FTEs**, please leave the associated fields empty and report only the totals.

Full-time equivalent (FTE)


R&D may be carried out by persons who work solely on **R&D** projects or by persons who devote only part of their time to **R&D**, and the balance to other activities such as testing, quality control and production engineering. To arrive at the total effort devoted to **R&D** in terms of personnel, it is necessary to estimate the full-time equivalent of these persons working only part-time in **R&D**.

Full-time equivalent (FTE) = Number of persons who work solely on R&D projects + the time of persons working only part of their time on R&D.

Example calculation: If out of four scientists engaged in **R&D** work, one works solely on **R&D** projects and the remaining three devote only one quarter of their working time to **R&D**, then: **FTE** = 1 + 1/4 + 1/4 = 1.75 scientists.

| | Res | searchers and research managers | Men (FTEs) | Women (FTEs) | Non-binary persons (FTEs) | Total (FTEs) |
|-----|-----|-------------------------------------------------------------------------------------------------------------------|---------------|-----------------|---------------------------------------------------|-----------------|
| | a. | Scientists, social scientists, engineers and researchers Include software developers and programmers | B20045_o1_y1 | B20045_o2_y1 | B20045_o3_y1 | B20045_y1 |
| | | | B20045_o1_y2 | B20045_o2_y2 | B20045_o3_y2 | B20045_y2 |
| | b. | Senior research managers | | | | |
| | | Total researchers and research managers | B20045_01_y3 | B20045_o2_y3 | B20045_o3_y3 | B20045_y3 |
| | R&I | D technical, administrative and support staff | B20045_o1_y4 | B20045_o2_y4 | B20045_o3_y4 | B20045_y4 |
| | c. | Technicians, technologists and research assistants Include software technicians | | | | |
| | d. | Other R&D technical, administrative and support staff | B20045_o1_y5 | B20045_o2_y5 | B20045_o3_y5 | B20045_y5 |
| | u. | | B20045_o1_y6 | B20045_o2_y6 | B20045_o3_y6 | B20045_y6 |
| | | Total R&D technical, administrative and support staff | | | | |
| | Oth | er R&D occupations | B20045_o1_y7 | B20045_o2_y7 | B20045_o3_y7 | B20045_y7 |
| | e. | On-site R&D consultants and contractors | | | | |
| | | Total in-house R&D personnel within Canada | B20040_o1 | B20040_o2 | B20040_o3 | B20040 |
| | | (sum of questions a. to e.) | | | | |
| | | | | | Percentago software-re activities B20046 | lated |
| 18. | | his organization's total in-house R&D personnel reported above, where the software-related activities? | | | | % |
| | | | | | | |
| | | | | | | |
| | | | | | | |

19. In 2023, how were the total in-house R&D personnel distributed by province or territory? Please report in full-time equivalents (FTE).



Technology and technical assistance payments in 2023

20. In 2023, how much did this organization pay to other organizations for technology and technical assistance? Please report all amounts in thousands of Canadian dollars. Report "1" for payments made between \$1 and \$999.

| | Payments made within Canada | Payments made outside Canada |
|-------------------------------------------------------------------------------------------------|-----------------------------|---------------------------------|
| Payments made to affiliated organizations | CAN\$ '000 E46099_pc1 | CAN\$ '000 E43043_pc1 |
| . Patents | \$,000 |) \$,(|
| o. Copyrights | \$,000 | |
| . Trademarks | \$,000 |) \$,0 |
| I. Industrial designs | E46099_pc4 | E43043_pc4 |
| . Integrated circuit topography | E46099_pc5 | E43043_pc5 |
| | E46099_pc6 | E43043_pc6 |
| . Original software | E46099_pc7 | E43043_pc7 |
| . Packaged or off-the-shelf software | \$,001 |) \$,(E43043_pc8 |
| . Databases (useful life exceeding one year) | \$,00 |) \$,0 |
| Other technology and technical assistance Include technical assistance, industrial processes | E46099_pc9 | E43043_pc9 |
| and know-how | E46220 | υ φ , (E43040 |
| Total payments made to affiliated organizations (sum of questions a. to i.) | \$,000 |) \$,(|
| ayments made to other organizations, companies or individuals | S E46101_pc1 | E43044_pc1 |
| Patents | \$,000 |) \$,(|
| Copyrights | \$,000 | A |
| Trademarks | \$,000 |) \$,0 |
| n. Industrial designs | E46101_pc4 | E43044_pc4 |
| | E46101_pc5 | E43044_pc5 |
| . Integrated circuit topography | \$,000 |) \$,(|
| . Original software | \$,000 E46101_pc7 |) \$,(,(|
| . Packaged or off-the-shelf software | \$,000 |) \$,(|
| . Databases (useful life exceeding one year) | \$,000 |) \$,(|
| Other technology and technical assistance Include technical assistance, industrial processes | E46101_pc9 | E43044_pc9 |
| and know-how | \$,000 | |
| | E46230 | E43050 |
| Total payments made to other organizations, | |) \$(|
| | \$,000 E46260 |) \$. E43060 |

| Plea | 2023 , how much did this organization receive from other o ase report all amounts in thousands of Canadian dollars . ort "1" for payments received between \$1 and \$999 . | rganiz | zations for technology and | d techn | ical assistance? |) |
|------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|------------------------------------------------|---------|---------------------------------------------|------|
| пер | are in an paymente received between y I and yada. | | Payments received | | Payments recei | |
| Pay | ments received from affiliated organizations | | from within Canada CAN\$ '000 E46102_pc1 | | from outside Ca CAN\$ '000 E63042_pc1 | nada |
| a. | Patents | \$ | ,000 | \$ | E03042_µt1 | |
| ι. | | ψ | E46102_pc2 | ψ | E63042_pc2 | , |
|). | Copyrights | \$ | ,000 E46102_pc3 | \$ | E63042_pc3 | |
|). | Trademarks | \$ | ,000 E46102_pc4 | \$ | E63042_pc4 | |
| d. | Industrial designs | \$ | ,000 E46102_pc5 | \$ | E63042_pc5 | |
| э. | Integrated circuit topography | \$ | ,000 | \$ | | |
| | Oviginal aaftuurra | \$ | E46102_pc6 | \$ | E63042_pc6 | |
| • | Original software | Ψ | E46102_pc7 | • | E63042_pc7 | |
|) . | Packaged or off-the-shelf software | \$ | E46102_pc8 | \$ | E63042_pc8 | |
| ۱. | Databases (useful life exceeding one year) | \$ | ,000 | \$ | | |
| | Other technology and technical assistance Include technical assistance, industrial processes | | E46102_pc9 | φ | E63042_pc9 | |
| | and know-how | \$ | ,000 E46240 | \$ | E63030 | |
| | Total payments received from affiliated organizations (sum of question a. to i.) | \$ | ,000 | \$ | | |
| | ments received from other organizations, | • | | | | |
| ,011 | npanies or individuals | \$ | E46103_pc1 | \$ | E63043_pc1 | |
| | Patents | Φ | ,000 E46103_pc2 | Φ | E63043_pc2 | |
| ζ. | Copyrights | \$ | ,000 E46103_pc3 | \$ | E63043_pc3 | |
| | Trademarks | \$ | ,000 E46103_pc4 | \$ | E63043_pc4 | |
| n. | Industrial designs | \$ | 000 \$ | \$ | E03043_p04 | |
| | | | E46103_pc5 | | E63043_pc5 | |
| ۱. | Integrated circuit topography | \$ | ,000 E46103_pc6 | \$ | E63043_pc6 | |
|). | Original software | \$ | ,000 E46103_pc7 | \$ | E63043_pc7 | |
|). | Packaged or off-the-shelf software | \$ | ,000 E46103_pc8 | \$ | E63043_pc8 | |
| | Databases (useful life exceeding one year) | \$ | .000 | \$ | 2000-0_000 | |
| 1· | Other technology and technical assistance | Ŷ | E46103_pc9 | , | E63043_pc9 | |
| | Include technical assistance, industrial processes and know-how | \$ | ,000 | \$ | | |
| | | | E46250 | | E63040 | |
| | Total payments received from other organizations, companies or individuals (sum of question j. to r.). | \$ | ,000 | \$ | | |
| | otal payments received from other organizations | | E46270 | | E63050 | |
| fo | r technology and technical assistance um of question a. to r.) | \$ | ,000 | \$ | | |

Changes or events

| 22. | Indicate any changes or events that affected the reported values for this business or organization compared with the last reporting period. |
|-----|---------------------------------------------------------------------------------------------------------------------------------------------|
| | Mark all that apply. |
| | B00316_r1 |
| | Outsourcing of R&D projects |
| | |
| | |
| | Initiation of new R&D projects |
| | B00316_r3 |
| | Completion of existing R&D projects |
| | B00316_r4 |
| | Major change in funding of R&D projects (loss of funding) |
| | B00316_r5 |
| | Major change in funding of R&D projects (increase in funding) |
| | B00316_16 |
| | Organizational change that affected R&D activities (expansion, reduction, restructuring) |
| | B00316_r7 |
| | Economic change that affected R&D activities |
| | B00316_r11 |
| | |
| | B00302_115 |
| | Other reason — specify: |
| | |
| | OR |
| | B00302_t17 |
| | No changes or events |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | B00316_r11 Lack of availability of qualified R&D personnel B00302_t15 Other reason — specify: OR |

| Contact person | |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------|
| 23. Statistics Canada may need to contact the person who completed this questionnaire for further information. | |
| If the contact person is the same as on cover page, please check \bigcirc \rightarrow Go to "Feedback" | |
| Otherwise, who is the best person to contact about this questionnaire? | |
| First name | |
| | |
| Last name | |
| | |
| Title | |
| | |
| Email address (Example: user@example.gov.ca) | |
| | |
| Telephone number (including area code) Extension number Fax number (including area code) Example: 123-123-1234 (if applicable) Example: 123-123-1234 | |
| Feedback | _ |
| | |
| 24. How long did it take to complete this questionnaire? Include the time spent gathering the necessary information | Minutes |
| 24. How long did it take to complete this guestionnaire? Include the time spent gathering the necessary information | Minutes |
| 24. How long did it take to complete this questionnaire? | Minutes |
| 24. How long did it take to complete this questionnaire? Include the time spent gathering the necessary information. Hours 25. We invite your comments about this questionnaire. | Minutes |
| 24. How long did it take to complete this questionnaire? Include the time spent gathering the necessary information. Hours 25. We invite your comments about this questionnaire. | Minutes |
| 24. How long did it take to complete this questionnaire? Include the time spent gathering the necessary information. Hours 25. We invite your comments about this questionnaire. | Minutes |
| 24. How long did it take to complete this questionnaire? Include the time spent gathering the necessary information. Hours 25. We invite your comments about this questionnaire. | Minutes |
| 24. How long did it take to complete this questionnaire? Include the time spent gathering the necessary information. Hours 25. We invite your comments about this questionnaire. | Minutes |
| 24. How long did it take to complete this questionnaire? Include the time spent gathering the necessary information. Hours 25. We invite your comments about this questionnaire. | Minutes |
| 24. How long did it take to complete this questionnaire? Include the time spent gathering the necessary information. Hours 25. We invite your comments about this questionnaire. | Minutes |
| 24. How long did it take to complete this questionnaire? Include the time spent gathering the necessary information. Hours 25. We invite your comments about this questionnaire. | Minutes |
| 24. How long did it take to complete this questionnaire? Include the time spent gathering the necessary information. Hours 25. We invite your comments about this questionnaire. | Minutes |
| 24. How long did it take to complete this questionnaire? Include the time spent gathering the necessary information. Hours 25. We invite your comments about this questionnaire. | Minutes |

Confidentiality

Your answers are confidential.

By law, Statistics Canada is prohibited from releasing any information it collects that could identify any person, business, or organization, unless consent has been given by the respondent, or as permitted by the *Statistics Act*.

Statistics Canada will use information from the survey for statistical purposes.

Data-sharing agreements

To reduce response burden, Statistics Canada has entered into data sharing agreements with provincial and territorial statistical agencies and other government organizations, which have agreed to keep the data confidential and use them only for statistical purposes. Statistics Canada will only share data from this survey with those organizations that have demonstrated a requirement to use the data.

Section 11 of the *Statistics Act* provides for the sharing of information with provincial and territorial statistical agencies that meet certain conditions. These agencies must have the legislative authority to collect the same information, on a mandatory basis, and the legislation must provide substantially the same provisions for confidentiality and penalties for disclosure of confidential information as the *Statistics Act*. Because these agencies have the legal authority to compel businesses to provide the same information, consent is not requested and businesses may not object to the sharing of the data.

For this survey, there are **Section 11** agreements with the provincial and territorial statistical agencies of Newfoundland and Labrador, Nova Scotia, New Brunswick, Quebec, Ontario, Manitoba, Saskatchewan, Alberta, British Columbia and the Yukon. The shared data will be limited to information on in-house research and development expenditures (Question 12) and inhouse research and development personnel (Question 19) pertaining to business establishments located within the jurisdiction of the respective province or territory.

Section 12 of the *Statistics Act* provides for the sharing of information with federal, provincial or territorial government organizations. Under **Section 12**, you may refuse to share your information with any of these organizations by writing a letter of objection to the Chief Statistician and returning it with the completed questionnaire. Please specify the organizations with which you do not want to share your data.

For this survey, there are **Section 12** agreements with the statistical agencies of Prince Edward Island, the Northwest Territories and Nunavut. The shared data will be limited to information on in-house research and development expenditures (Question 12) and in-house research and development personnel (Question 19) pertaining to business establishments located within the jurisdiction of the respective province or territory.

Record linkages

To enhance the data from this survey and to reduce the reporting burden, Statistics Canada may combine the acquired data with information from other surveys or from administrative sources.

Thank you for completing this questionnaire. Please retain a copy for your records. Visit our website, www.statcan.gc.ca